Gaudium IVF and Women Health Limited has concluded its public offering with significant momentum, as the subscription window closed on February 24, 2026. The initial public offering, valued at 165 crore, saw a surge in interest during the final hours of bidding. Total subscription levels reached 3 times on the penultimate day, eventually strengthening as retail and non-institutional participants dominated the book. The grey market premium for the issue has settled at approximately 5 per share. Based on the upper price band of 79, market observers estimate a listing price near 84, representing a potential 6.33% debut gain. This follows a period of volatile sentiment where premiums reached as high as 11% earlier in the bidding cycle. The IPO structure consists of a fresh issue of 90 crore and an offer-for-sale of 75 crore. The company intends to deploy 50 crore of the proceeds to establish 19 new IVF centers across India over the next three years. An additional 20 crore is earmarked for the repayment or prepayment of outstanding debt, aiming to further strengthen a balance sheet that already shows a healthy debt-to-equity ratio of 0.38. Financial performance for the 2025 fiscal year highlights a robust growth trajectory. Revenue rose to 70.72 crore, marking a significant jump from 47.89 crore in the previous year. Net profit also saw a sharp increase, reaching 19.13 crore compared to 10.32 crore in 2024. The company maintains an EBITDA margin of 40.48% and a return on equity of 21.25%, though these figures have moderated slightly from previous peaks. Operating via a hub-and-spoke model, the company currently manages 7 hubs and 28 spokes across India. This positioning is strategic, as the domestic fertility services market is projected to expand from 1.81 billion USD in 2025 to over 9 billion USD by 2035. This represents a compound annual growth rate of 17.5%, driven by rising infertility rates and increasing awareness of assisted reproductive technologies. The allotment process is scheduled for completion on February 25, 2026. Shares are expected to be credited to demat accounts by February 26, followed by the official listing on the BSE and NSE on February 27, 2026. This marks a milestone as the first pure-play fertility services provider to join the Indian mainboard exchange.